Equities research analysts expect that Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) will post earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Actinium Pharmaceuticals’ earnings. Actinium Pharmaceuticals reported earnings of ($0.06) per share in the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The business is scheduled to announce its next earnings results on Tuesday, March 17th.
According to Zacks, analysts expect that Actinium Pharmaceuticals will report full year earnings of ($0.16) per share for the current year. For the next financial year, analysts expect that the firm will report earnings of ($0.17) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Actinium Pharmaceuticals.
Actinium Pharmaceuticals (NASDAQ:ATNM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04).
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Read More: Dividend Reinvestment Plan (DRIP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.